Advair Powder
Product Images NDC 50090-4505

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair (NDC 50090-4505). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)

Chemical structure diagram of fluticasone propionate, the active ingredient in ADVAIR DISKUS inhalation powder. The diagram shows the molecular arrangement and bonds typical for this corticosteroid compound.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)

Chemical structure diagram depicting two distinct molecules representing the active ingredients fluticasone propionate and salmeterol in the ADVAIR DISKUS formulation.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)

A line graph comparing the percentage change in FEV1 over 12 weeks and at an endpoint among four groups: ADVAIR DISKUS 100/50 twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph shows progression over weeks with the highest increase seen in the ADVAIR DISKUS group.*

FDA Label Image

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)

A line graph showing percentage change in FEV1 over 12 hours for four groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The graph tracks lung function improvement over time post-dose, with ADVAIR DISKUS showing the highest peak change followed by Salmeterol, Fluticasone propionate, and Placebo.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)

A line graph comparing the percent change in FEV1 relative to day 1 baseline over a 12-hour period for different treatments including ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg once daily, fluticasone propionate 100 mcg twice daily, and placebo. The x-axis represents time in hours, and the y-axis shows percent change from baseline, illustrating the respiratory function response to each treatment.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)

A line graph comparing percent change in FEV1 over 24 weeks among three groups: ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo. The graph plots percent change on the y-axis and weeks on the x-axis, showing higher improvement with ADVAIR DISKUS 250/50 over time compared to other groups.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)

Line graph showing percentage change in FEV1 over 24 weeks comparing ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo. The graph includes baseline FEV1 values and sample sizes for each group at various time points, illustrating treatment effects on lung function over time.*

FDA Label Image

Figure A (Advair Diskus Spl Graphic 08)

Illustration of an ADVAIR DISKUS inhalation device containing fluticasone propionate and salmeterol 100/50 micrograms per dose. The device parts labeled include the outer case, mouthpiece, counter, thumb grip, and lever. This powder inhaler is used for respiratory route administration.*

FDA Label Image

Figure B (Advair Diskus Spl Graphic 09)

Illustration showing a person holding an ADVAIR DISKUS inhaler in their hand, demonstrating the motion of sliding the top part of the device horizontally to activate it for use.*

FDA Label Image

Figure C (Advair Diskus Spl Graphic 10)

Illustration showing a close-up of a person holding an ADVAIR DISKUS inhaler, demonstrating how to grip the device properly, with a directional arrow indicating a step in the inhalation process.*

FDA Label Image

Figure D (Advair Diskus Spl Graphic 11)

An instructional illustration showing a woman holding and using a purple ADVAIR DISKUS inhaler device for respiratory powder inhalation. The image depicts the user preparing to inhale the medication, demonstrating proper inhaler usage technique.*

FDA Label Image

Figure E (Advair Diskus Spl Graphic 12)

An instructional illustration showing a woman in a purple shirt using a purple ADVAIR DISKUS inhaler for respiratory (inhalation) administration of fluticasone propionate and salmeterol powder medication.*

FDA Label Image

Figure F (Advair Diskus Spl Graphic 13)

An instructional illustration showing hands demonstrating the opening mechanism of an ADVAIR DISKUS device. The image depicts the user sliding a latch on the inhaler to prepare it for use, indicated by an arrow pointing in the direction of the slide.*

FDA Label Image

Figure G (Advair Diskus Spl Graphic 14)

An illustration showing a woman rinsing her mouth with water over a sink. The image likely relates to a step in inhalation medication use, emphasizing mouth rinsing after inhaler use.*

FDA Label Image

Figure H (Advair Diskus Spl Graphic 15)

ADVAIR DISKUS 100/50 inhalation powder device in purple, labeled with fluticasone propionate and salmeterol 100 mcg/50 mcg strength. The label indicates 60 blisters inside, with space for pouch opened and use by dates. The powder is for respiratory inhalation.*

FDA Label Image

Label Image (Lbl500904505)

Label for ADVAIR DISKUS 500 MCG/50 MCG inhalation powder by A-S Medication Solutions. Each blister contains 500 mcg fluticasone propionate and 72.5 mcg salmeterol xinafoate equivalent to 50 mcg salmeterol base, with lactose. Pack includes 1 foil strip of 60 blisters. Storage and dosage instructions included on label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.